多佐剂个体化新抗原疫苗：微调抗癌T细胞

IF 42.5 1区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cell Pub Date : 2025-09-18 DOI:10.1016/j.cell.2025.08.025

Hejia Henry Wang, Neeha Zaidi

{"title":"多佐剂个体化新抗原疫苗：微调抗癌T细胞","authors":"Hejia Henry Wang, Neeha Zaidi","doi":"10.1016/j.cell.2025.08.025","DOIUrl":null,"url":null,"abstract":"Personalized cancer vaccines aim to broaden the anti-tumor T cell repertoire by targeting neoantigens unique to each patient’s tumor, but immunogenicity has been inconsistent. In this issue of Cell, Blass, Keskin, Tu et al. evaluate NeoVaxMI, a multi-adjuvant personalized synthetic long-peptide vaccine administered with nivolumab in patients with melanoma. NeoVaxMI elicited stronger CD4+ and CD8+ responses than earlier iterations, and vaccine-induced T cells trafficked to regressing metastatic lesions.","PeriodicalId":9656,"journal":{"name":"Cell","volume":"16 1","pages":""},"PeriodicalIF":42.5000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells\",\"authors\":\"Hejia Henry Wang, Neeha Zaidi\",\"doi\":\"10.1016/j.cell.2025.08.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Personalized cancer vaccines aim to broaden the anti-tumor T cell repertoire by targeting neoantigens unique to each patient’s tumor, but immunogenicity has been inconsistent. In this issue of Cell, Blass, Keskin, Tu et al. evaluate NeoVaxMI, a multi-adjuvant personalized synthetic long-peptide vaccine administered with nivolumab in patients with melanoma. NeoVaxMI elicited stronger CD4+ and CD8+ responses than earlier iterations, and vaccine-induced T cells trafficked to regressing metastatic lesions.\",\"PeriodicalId\":9656,\"journal\":{\"name\":\"Cell\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":42.5000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cell.2025.08.025\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.cell.2025.08.025","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

个性化癌症疫苗旨在通过针对每个患者肿瘤特有的新抗原来扩大抗肿瘤T细胞库，但免疫原性一直不一致。在这一期的Cell中，Blass, Keskin， Tu等人评估了NeoVaxMI，一种多佐剂个性化合成长肽疫苗，与nivolumab一起用于黑色素瘤患者。与早期的迭代相比，NeoVaxMI引发了更强的CD4+和CD8+反应，并且疫苗诱导的T细胞被运输到退化的转移性病变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells

Personalized cancer vaccines aim to broaden the anti-tumor T cell repertoire by targeting neoantigens unique to each patient’s tumor, but immunogenicity has been inconsistent. In this issue of Cell, Blass, Keskin, Tu et al. evaluate NeoVax^MI, a multi-adjuvant personalized synthetic long-peptide vaccine administered with nivolumab in patients with melanoma. NeoVax^MI elicited stronger CD4⁺ and CD8⁺ responses than earlier iterations, and vaccine-induced T cells trafficked to regressing metastatic lesions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell 生物-生化与分子生物学

CiteScore

110.00

自引率

0.80%

发文量

396

审稿时长

2 months

期刊介绍： Cells is an international, peer-reviewed, open access journal that focuses on cell biology, molecular biology, and biophysics. It is affiliated with several societies, including the Spanish Society for Biochemistry and Molecular Biology (SEBBM), Nordic Autophagy Society (NAS), Spanish Society of Hematology and Hemotherapy (SEHH), and Society for Regenerative Medicine (Russian Federation) (RPO). The journal publishes research findings of significant importance in various areas of experimental biology, such as cell biology, molecular biology, neuroscience, immunology, virology, microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. The primary criterion for considering papers is whether the results contribute to significant conceptual advances or raise thought-provoking questions and hypotheses related to interesting and important biological inquiries. In addition to primary research articles presented in four formats, Cells also features review and opinion articles in its "leading edge" section, discussing recent research advancements and topics of interest to its wide readership.